Study Reveals Dramatic Price Difference Between Ozempic and Generic Diabetes Medicines

A study suggests that Novo Nordisk's diabetes drug Ozempic could be manufactured for less than $5 a month, despite the company charging close to $1,000 per month in the U.S. The findings raise questions about the high cost of the drug and similar treatments, especially as demand for them increases while insurers drop coverage due to cost. Novo Nordisk defended its pricing, citing research and development expenses and offering savings programs, but the study suggests that these drugs could be produced at significantly lower prices, enabling wider access.